Vimarsana
Biggest News Aggregation in the World

Blue Future Partners News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Blue Future Partners. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Blue Future Partners Today - Breaking & Trending Today

Editor's take: The week that was — Dec 12-17 - Vimarsana News

Editor's take: The week that was — Dec 12-17

This is the last edition of the weekly wrap for this year.

The LP View: Early-stage VCs can have the best risk-return profile, says Blue Future Partners - Vimarsana News

The LP View: Early-stage VCs can have the best risk-return profile, says Blue Future Partners

The firm plans to increase exposure to APAC in the coming years.

Vietnam's VC Market Matures as Investments Reach Record Highs - Vimarsana News

Vietnam's VC Market Matures as Investments Reach Record Highs

2021 was a record year for venture capital (VC) investments in Vietnam, driven by a maturing technology startup ecosystem, an increasing number of later stage investments, and rising participation from both local and foreign investors eager to tap into Vietnam’s burgeoning digital economy, a new report by Silverhorn says.

Ascend Vietnam Ventures closes debut fund at over $50m - Vimarsana News

Ascend Vietnam Ventures closes debut fund at over $50m

The fund is aiming to build the next wave of globally iconic startups emerging from Vietnam.

China Digest: Biopharma startup Alebund raises $60m; Revere VC closes seed round - Vimarsana News

China Digest: Biopharma startup Alebund raises $60m; Revere VC closes seed round

China Digest: Biopharma startup Alebund raises $60m; Revere VC closes seed round May 11, 2021 Chinese biopharmaceutical startup Alebund Pharmaceuticals has secured $60 million in a Series B round, while San Francisco and Hong Kong-based asset management firm Revere VC has closed its seed round. Alebund Pharma nets $60m in Series B round Alebund Pharmaceuticals, a biopharmaceutical startup that develops innovative therapies for the treatment of renal diseases, has bagged $60 million in a Series B round of financing, the startup announced on May 9. The Series B round was led by Quan Capital, a...